Home > Healthcare & Medical Devices > Dermatology Drugs Market

Dermatology Drugs Market - By Indication (Psoriasis, Atopic Dermatitis, Acne, Skin Cancer), By Route of Administration (Parenteral Injection, Topical, Oral), By Distribution Channel (Hospital, Retail), Global Forecast (2023 – 2032)

  • Report ID: GMI6311
  • Published Date: Jul 2023
  • Report Format: PDF

Dermatology Drugs Industry Analysis

Dermatology Drugs Market size was valued to be USD 27.1 billion in 2022 and is expected to reach USD 73.5 billion in 2032 with a CAGR of 10.5% from 2023 to 2032. Factors propelling the growth of market include increasing prevalence of skin disorders, advancements in research and development, expanding geriatric population, and technological innovations in drug delivery such as nanotechnology which involves the use of nanoparticles to deliver drugs to specific skin layers or cells.
 

Dermatology Drugs Market

To get more details on this report: Request Free Sample PDF
 

Furthermore, rising awareness about skin diseases and increased desire for quick diagnostics are driving the dermatological drugs market forward. Increasing demand for novel pharmaceuticals and rising R&D spending in the development of new drugs will boost market revenue.
 

Additionally, pharmaceutical companies and research institutions continue to invest in dermatology research, leading to the discovery of new therapeutic targets and drug development. Advances in treatment options for various skin conditions have further expanded the scope of dermatology treatments, driving market growth.
 

COVID-19 Impact

The COVID-19 pandemic has led to increased usage of personal protective equipment (PPE) among the general population and healthcare workers. PPE usage has been shown to trigger dermatological conditions such as facial dermatoses, contact dermatitis, acne, and friction dermatitis. Furthermore, the long-term usage of protective clothing and contacting disinfectants can disrupt the skin barrier, increasing the risk for infections and autoimmune conditions. The most prevalent dermatological conditions related to COVID-19 include exanthematous (morbilliform) rash, pernio-like acral lesions, urticaria, varicella-like eruption, papulosquamous rash and retiform purpura.
 

The COVID-19 pandemic has disrupted society through government lockdowns, quarantine measures, isolation, fear of infection, the stress of employment, economic instability, changes in educational delivery, and bereavement of loved ones. Moreover, these unique psychosocial stressors have been linked to exacerbations of pre-existing psoriasis, eczema, telogen effluvium, and atopic dermatitis. Furthermore, the pandemic has expanded the use of tele dermatology, making dermatological care more accessible to patients. The increased incidence of these dermatological diseases along with increased adoption of teleconsultations boosted the market growth in 2020.
 

However, disruptions in supply chains resulting in medication shortages and reduction in number of patient visits due to lockdowns has significantly impacted the market. With the reduction in the number of coronavirus cases, the market is resuming its normal growth. 
 

Dermatology Drugs Market Trends

Dermatologists were exploring the use of drug combinations and sequential therapy approaches to enhance treatment outcomes in certain skin conditions. Combining different classes of drugs or using them in a stepwise manner showed promise in achieving better disease control. In addition, biologic drugs, particularly monoclonal antibodies targeting specific cytokines or immune pathways, are gaining significant traction in the treatment of various autoimmune skin conditions. Drugs like TNF-alpha inhibitors, IL-17 inhibitors, and IL-23 inhibitors are becoming the standard of care for moderate to severe psoriasis and other inflammatory skin diseases due to their high efficacy and targeted approach.
 

Dermatology Drugs Indication Segmentation

Dermatology Drugs Market Size, By Indication,

To get more details on this report: Request Free Sample PDF
 

Based on indication type, the dermatology drugs market is categorized into psoriasis, atopic dermatitis, acne, skin cancer, and other indications. The psoriasis segment held the largest market share of 48.2% in 2022. Psoriasis is a common skin disorder, affecting millions of people worldwide. As per the publication by the National Psoriasis Foundation/USA, 2023, around 125 million people worldwide (2-3 percent of the total population) have psoriasis. The high prevalence of psoriasis drives the demand for effective and innovative dermatology drugs to manage and treat the condition.
 

Dermatology Drugs Route of Administration Segmentation  

Dermatology Drugs Market Share, By Route of Administration

To get more details on this report: Request Free Sample PDF
 

Based on route of administration, the dermatology drugs market is bifurcated into parenteral injection, topical, and oral. The parenteral injection segment was anticipated to be worth of USD 21.2 billion in 2022 and is expected to grow at 10.5% CAGR during the forecast period. Parenteral administration enables accurate and targeted medication administration. Dermatology medications delivered by injections or infusions can reach the afflicted tissues or skin layers directly, increasing effectiveness and lowering the risk of systemic adverse effects, propelling the market further.
 

Dermatology Drugs Distribution Channel Segmentation  

Based on distribution channel, the dermatology drugs market is classified into hospital pharmacies and retail pharmacies. The hospital pharmacies segment held dominant market share of around 76.5% in 2022 and is expected to grow at a significant pace of 10.6% during the forecast period. Hospitals has specialised dermatology departments equipped with dermatology diagnostic devices and dermatology treatment devices. Dermatology drugs are readily available in hospital pharmacies to assist these specialised services.
 

In addition, hospital pharmacies often have access to high-cost biologic therapies used in the treatment of severe skin conditions like psoriasis and pemphigus vulgaris. These biologics may require special storage and handling, which hospital pharmacies are well-equipped to manage.
 

Dermatology Drugs Regional Analysis

North America Dermatology Drugs Market Size

North America dermatology drugs market accounted for significant revenue in 2022 and is expected to reach USD 10.7 billion in 2032 with a CAGR of 10.3% from 2023-2032. North America boasts a well-established and advanced healthcare infrastructure. The region has a robust network of hospitals, clinics, and specialty dermatology centers that facilitate the diagnosis and treatment of dermatological disorders. This infrastructure supports the accessibility and availability of dermatology drugs, contributing to market progress.
 

Moreover, there is an increasing awareness about skin health among the general population in North America. Patients are more proactive in seeking medical attention for skin diseases, leading to early diagnosis and treatment initiation. Improved patient awareness and diagnosis drive the demand for dermatology drugs in the region.
 

Dermatology Drugs Market Leaders

There are several significant competitors in the highly competitive dermatology drugs companies. The prominent players are Novartis AG, Amgen Inc., AbbVie Inc., Johnson & Johnson, Leo Pharma A/S, Eli Lilly and Company, GlaxoSmithKline Plc, AstraZeneca plc, Pfizer Inc., Merck KGaA, Lupin, F. Hoffmann-La Roche Ltd., and Sanofi. To keep a competitive advantage in the market, such companies are putting various tactics into practice, including partnerships, mergers, acquisitions, collaborations, and product launches.
 

Dermatology Drugs Market News:

  • In January 2022, Pfizer Inc. announced that the FDA has approved CIBINQO (abrocitinib), an oral, once-daily Janus kinase 1 (JAK1) inhibitor, for the treatment of adults with refractory, moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies is contraindicated.
     
  • In June 2021, Novartis announced that the FDA has authorised Cosentyx (secukinumab) for the treatment of moderate to severe plaque psoriasis in paediatric children six years and older who are not candidates for systemic medication or phototherapy.
     

The dermatology drugs market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2018 to 2032 for the following segments:

Click here to Buy Section of this Report


Market Size, By Indication Type

  • Psoriasis
  • Atopic dermatitis
  • Acne
  • Skin cancer
  • Other indications

Market Size, By Route of Administration

  • Parenteral injection
  • Topical
  • Oral

By Distribution Channel

  • Hospital pharmacies
  • Retail pharmacies

The above information is provided for the following regions and countries:

  • North America 
    • U.S.
    • Canada 
  • Europe 
    • Germany
    • UK
    • France
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • Rest of Asia Pacific 
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America 
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • Rest of Middle East & Africa

 

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Dermatology drugs industry size reached USD 27.1 billion in 2022 and will record USD 73.5 billion by the end of 2032 owing to the increasing prevalence of skin disorders along with the higher advancements in research and development

Parenteral injection route of administration segment is expected to witness 10.5% CAGR from 2023-2032 driven by the rising obligation to offer accurate and targeted medication administration

The hospital pharmacies distribution channel segment held 76.5% of the dermatology drugs industry share in 2022 due to the robust presence of specialized departments as well as diagnostic devices and treatment devices

North America size is expected to be valued at USD 10.7 billion by 2032 driven by the strong presence of well-established and advanced healthcare infrastructure in the region

Buy Now

Access to only 1 person; cannot be shared; cannot be printed
Access for 2 to 5 users only within same department of one company
Access to a company wide audience; includes subsidiary companies or other companies within a group of companies

Premium Report Details

  • Base Year: 2022
  • Companies covered: 13
  • Tables & Figures: 203
  • Countries covered: 20
  • Pages: 113
Inquiry Before Buying

Budget constraints? Get in touch with us for special pricing

Request Discount